Go Back   HER2 Support Group Forums > Clinical Trials
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Thread Tools Display Modes
Prev Previous Post   Next Post Next
Old 09-21-2013, 12:06 PM   #1
Senior Member
'lizbeth's Avatar
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Talking Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Br

Wow, a future study without chemo? Still pending, but one to watch!

ClinicalTrials.gov Identifier:

This study is not yet open for participant recruitment.
Verified September 2013 by Sidney Kimmel Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center

ClinicalTrials.gov Identifier:
First received: September 3, 2013
Last updated: September 11, 2013
Last verified: September 2013
History of Changes

Purpose This research is being done to determine if early changes on a type of imaging procedure called PET (Positron Emission Tomography) can predict which patients are most likely to respond to the combination of trastuzumab and pertuzumab when given prior to surgery.

Condition Intervention Phase Breast Cancer
Procedure: Positron emission tomography (PET)
Drug: Trastuzumab
Drug: Pertuzumab
Phase 2

Study Type: Interventional Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment Official Title: A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer
Resource links provided by NLM:

Genetics Home Reference related topics: breast cancer
MedlinePlus related topics: Breast Cancer Cancer
Drug Information available for: Trastuzumab Pertuzumab
U.S. FDA Resources

Further study details as provided by Sidney Kimmel Comprehensive Cancer Center:

Primary Outcome Measures:
  • Change in SUV on FDG PET [ Time Frame: 3 months ] [ Designated as safety issue: No ]To correlate baseline and change (day 15) in SUV on FDG PET with pathological complete response (pCR) in patients treated with preoperative pertuzumab/trastuzumab

Secondary Outcome Measures:
  • Change in ptDNA with response [ Time Frame: 3 months ] [ Designated as safety issue: No ]To correlate PIK3CA mutation status and other genomic alterations (mutations/somatic rearrangements) qualitatively and quantitatively in plasma tumor DNA (ptDNA) with pCR

  • Change in PI3K pathway activation with response [ Time Frame: 3 months ] [ Designated as safety issue: No ]To correlate PI3K pathway activation (e.g. PTEN low and/or PIK3CA mutation, HER 1-4 expression and/or phosphorylation) in tumor samples and pCR

  • Changes in Ki67 with response [ Time Frame: 3 months ] [ Designated as safety issue: No ]To correlate baseline and change (day 15) in Ki67 with pCR

Estimated Enrollment: 88 Study Start Date: September 2013 Estimated Study Completion Date: December 2016 Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)http://www.clinicaltrials.gov/ct2/sh...erjeta&rank=20
'lizbeth is offline   Reply With Quote

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump

All times are GMT -7. The time now is 07:35 PM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2023, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter